CN1130215C - Detoxicating and recovering medicine powder - Google Patents

Detoxicating and recovering medicine powder Download PDF

Info

Publication number
CN1130215C
CN1130215C CN01104485A CN01104485A CN1130215C CN 1130215 C CN1130215 C CN 1130215C CN 01104485 A CN01104485 A CN 01104485A CN 01104485 A CN01104485 A CN 01104485A CN 1130215 C CN1130215 C CN 1130215C
Authority
CN
China
Prior art keywords
medicine
radix
immune
disease
cortex moutan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN01104485A
Other languages
Chinese (zh)
Other versions
CN1310007A (en
Inventor
丁丛礼
丁赢
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN01104485A priority Critical patent/CN1130215C/en
Publication of CN1310007A publication Critical patent/CN1310007A/en
Application granted granted Critical
Publication of CN1130215C publication Critical patent/CN1130215C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Abstract

The present invention relates to medicine for treating immunological diseases caused by low immune function, immune dysfunction, immune deficiency, etc. The medicine is prepared from traditional Chinese medicine of alkanna tinctoria, wild ginseng, antelope horn, american ginseng, natural bezoar, unpeeled cortex moutan, ledebouriella root, Chinese caterpillar fungus, etc. according to a certain technology. The medicine can promote the conversion of lymphocyte, can increase the hemolysis capability of spleen plaque forming cells to increase antibody, can inhibit type III allergy, and can inhibit the formation of immune complex to decrease the activation of complement. The medicine can be used for treating the immunological diseases, such as lupus erythematosus, leukemia, scleroderma, dermatomyositis, ankylosing spondylitis, rheumatic diseases, rheumatoid arthritis, etc.

Description

A kind of medicine for the treatment of immune disease
The present invention relates to the medicine of immune diseases such as a kind of hypofunction, disorder, defective, specifically is to be the Chinese patent medicine that feedstock production forms with the Chinese herbal medicine, belongs to the field of Chinese medicines.
Systemic lupus erythematosus (sle) is that world's medical matters circle are referred to as one of four big difficult disease of wrecking the human life, and domestic and international interrelated data report, the sickness rate that every year should disease to be rapidly increasing progressively by a relatively large margin, to the mankind's threat not second to cancer and acquired immune deficiency syndrome (AIDS).In areas such as the Luo Qisite of the U.S., California, the sickness rate in its members of the same clan exceeds hundreds of times of general crowd up to 0.4-5%.Black people's sickness rate is three times in general crowd, and in the Black women of 15-45, per 245 people have a people to suffer from lupus erythematosus, is more common in the 15-25 young women in year especially.Before not using the 17-hydroxy-11-dehydrocorticosterone treatment, the primary disease mortality rate is very high, 80% patient dies from primary disease in 2 years, in recent years because the progress of diagnostic techniques and utilization 17-hydroxy-11-dehydrocorticosterone, the utilization of immunosuppressant, levamisole, antiviral drugs, antilymphocyte globulin thymosin and Chinese herbal medicine, the primary disease mortality rate progressively descends, and best survival rate has reached 80-85% in present 10 years.Though change is arranged, still, still have the part patient to die from organa parenchymatosums such as the heart, kidney, the brain infringement and the complication of primary disease because of various factors, particularly, systemic lupus erythematosus (sle) is the autoimmune disease that causes multiple organ injury.For immunologic hypofunction, disorder, defective caused such as immune diseases such as lupus erythematosus, scleroderma, dermatomyositis, leukemia, rheumatism, rheumatoid disease, ankylosing spondylitiss, up to the present, its cause of disease is still indeterminate, Therapeutic Method is also undesirable, great majority adopt international treatment convention, do interim control with immunosuppressant, because the toxic and side effects of immunosuppressant is big, part patient is not the death because of institute's disease that takes a disease, but fatal because of the toxic and side effects of medicine.Therefore, studying and a kind ofly can effectively regulate immune function and treat the medicine of lupus erythematosus, is one of important topic of current medical matters circle.
The object of the invention provides a kind of effective treatment immunologic hypofunction, disorder, the medicine such as immune diseases such as lupus erythematosus, scleroderma, dermatomyositis, leukemia, rheumatism, rheumatoid disease, ankylosing spondylitiss that defective caused.
Medicine of the present invention is that the Chinese herbal medicine by the following weight proportioning forms according to certain prepared:
Radix Arnebiae (Radix Lithospermi) 10~15
Radix Ginseng 3~5
Cornu Saigae Tataricae 2.5~6
Radix Panacis Quinquefolii 15~20
Radix Saposhnikoviae 30~40
Calculus Bovis 2~9
Unpeeled CORTEX MOUTAN 15~25
Cordyceps 8~15
Medicine of the present invention preferably is prepared from by the Chinese medicine of following weight parts:
Radix Arnebiae (Radix Lithospermi) 12
Radix Ginseng 4
Cornu Saigae Tataricae 4
Radix Panacis Quinquefolii 18
Radix Saposhnikoviae 35
Calculus Bovis 5
Unpeeled CORTEX MOUTAN 20
Cordyceps 10
Prepare in the middle of the required above-mentioned raw materials medicine of medicine of the present invention, Radix Ginseng preferably uses wild ginseng, and Calculus Bovis preferably uses natural Calculus Bovis.
Medicine of the present invention can be prepared into pharmaceutical dosage form commonly used clinically according to common process, preferred capsule or granule.
According to Traditional Chinese medical theory, all diseases are because of " institute of heresy gathers, and its gas must be empty ", and its treatment is according to being " healthy energy deposit in, heresy can not be done ".All are that disease is arranged from the principle of " diseases prevention ", also are contrary treatment " sick " and setting about.Such as " superior doctor treating the disease before its onset ... " or the like.Many clinically refractory disease utilization Chinese traditional treatments can be played obvious curative effects, also are this principle of treatment of the traditional Chinese medical science.In view of this, the author controls immune diseases such as lupus erythematosus, scleroderma, dermatomyositis, ankylosing spondylitis clinically, adopt the differentiation of tcm principle, the utilization Chinese herbal treatment is obtained better therapeutic effect, and reason has been used the principle of the traditional Chinese medical science " treatment must aim at the pathogenesis of disease " exactly.No matter the patient is with crossing or do not use immunosuppressant, its basic pathogenesis is that the friendship of " just " and " heresy " strives, Chinese medicine adopts and sets upright, eliminating evil and usefulness, elder generation's " legislation " on big therapeutic scheme, the principle of " legislation " then is that this type of patient is the so-called immunologic dysfunction of modern medicine, and the traditional Chinese medical science is then thought this theory of imbalance of YIN and YANG.
Therefore, medicine of the present invention is according to the Traditional Chinese medical theory prescription, Radix Arnebiae (Radix Lithospermi) removing heat from blood and promoting blood circulation, heat-clearing and toxic substances removing in the side, and pharmacological evaluation has analgesic, antiinflammatory action has inhibitory action to pathogenic microorganism, and low dose can excited heart, and heavy dose can be inhibition.Unpeeled CORTEX MOUTAN clearing away heat and cooling blood, promoting blood circulation to remove blood stasis, pharmacological evaluation confirm that antiinflammatory, antibiotic, antiulcer action are arranged, and analgesic, analgesia spasmolysis is arranged, and tangible anti-allergy action is arranged, to the internal organs that damaged particularly myocardial damage significant protective effect is arranged.Natural Calculus Bovis, the Cornu Saigae Tataricae conscience of reaching the same goal, heat-clearing and toxic substances removing, have one's ideas straightened out make eye bright, clearing liver-fire for calming endogenous wind.Good antipyretic effect is arranged, because the two has calmness, hypnosis and anticonvulsant action, so symptoms such as the hyperpyrexia that the immune disease that immunologic hypofunction is caused presented, fidgety, stupor, delirium, convulsions all have obvious curative effects.Wild ginseng, Radix Panacis Quinquefolii, Cordyceps QI invigorating, the logical YANG invigorating of temperature, the three is at immunology, has the combined effect that strengthens cellular immunization, strengthens humoral immunization, enhancing reticuloendothelial system phagocytic function and rising peripheral leukocytes, the three share and can strengthen removing free radical, strengthens coronary artery blood flow, expands peripheral vascular function, on the adjustment endocrine function, also have one's own knack, particularly wild ginseng and Radix Panacis Quinquefolii share, but inducement interferon strengthens the resistance to virus.The energy hemopoietic makes nucleated cell digital display work increase in erythrocyte in the blood, leukocyte, hemoglobin and the bone marrow, at aspects such as resisting fatigue, defying age, antiviral obvious effect is arranged.Assistant is analgesic to increase with the Radix Saposhnikoviae of temperature logical loose wind, removing dampness to relieve pain, the effect of antiinflammatory, analgesia, convulsion, and all medicines share tonify without causing stagnation, are not just hindering clearly, play the effect of clearing away heat and cooling blood, detoxifcation dissipating blood stasis, supplementing QI and nourishing YIN.Immune diseases such as the pyretic toxicity stasis of blood that is used for low grade fever, dysphoria with feverish sensation in the chest palms and soles, ecchymosis, spiritlessness and weakness, xerostomia, spontaneous perspiration, night sweat, insomnia is tied, the lupus erythematosus of impairment of both QI and YIN, scleroderma, dermatomyositis, leukemia, ankylosing spondylitis, rheumatism.
Medicine of the present invention has following function:
1, can promote lymphocytic conversion.
2, can improve spleen plaque forming cells haematolysis ability.
3, can bring out interferon, strengthen antiviral resistance.
4, can remove free radical, thus disease resistance enhancemen.
5, the pair cell immunity has regulating action with humoral immunization.
6, can suppress the reaction of III deformation attitude.
7, can strengthen the reticuloendothelial system phagocytic function, the rising peripheral leukocytes.The intractable pertinacious disease of immunity there is definite curative effect.
On the clinical drug of the present invention for immunologic hypofunction, disorder, defective caused has good therapeutic effect such as immune diseases such as lupus erythematosus, scleroderma, dermatomyositis, leukemia, rheumatism, rheumatoid disease, ankylosing spondylitiss.
Embodiment 1:
Raw material consists of (unit of weight gram)
Radix Arnebiae (Radix Lithospermi) 12
Wild ginseng 4
Cornu Saigae Tataricae 4
Radix Panacis Quinquefolii 18
Radix Saposhnikoviae 35
Calculus Bovis 5
Unpeeled CORTEX MOUTAN 20
Cordyceps 10
Manufacture method
Radix Panacis Quinquefolii, wild ginseng, Cordyceps, Radix Saposhnikoviae are used as medicine after concocting.Wild ginseng, Cornu Saigae Tataricae, natural Calculus Bovis are processed as the utmost point (surpassing) fine powder; Radix Arnebiae (Radix Lithospermi), Radix Panacis Quinquefolii, Cordyceps, unpeeled CORTEX MOUTAN, Radix Saposhnikoviae are boiled three times with the decocting of 5 times of amounts, and each 2 hours, taking liquid filtered, concentrates, pulverizing and last impalpable powder mixing granulation, pack, every bag of 6g.
Embodiment 2:
Raw material consists of (unit of weight gram)
Radix Arnebiae (Radix Lithospermi) 12
Wild ginseng 4
Cornu Saigae Tataricae 4
Radix Panacis Quinquefolii 18
Radix Saposhnikoviae 35
Calculus Bovis 5
Unpeeled CORTEX MOUTAN 20
Cordyceps 10
Manufacture method
Radix Panacis Quinquefolii, wild ginseng, Cordyceps, Radix Saposhnikoviae are used as medicine after concocting.Wild ginseng, Cornu Saigae Tataricae, natural Calculus Bovis are processed as the utmost point (surpassing) fine powder; Radix Arnebiae (Radix Lithospermi), Radix Panacis Quinquefolii, Cordyceps, unpeeled CORTEX MOUTAN, Radix Saposhnikoviae are boiled three times with the decocting of 5 times of amounts, and each 2 hours, taking liquid filters, concentrates, pulverizing mixes with last impalpable powder, and was encapsulated, each 0.5g.

Claims (4)

1, a kind of medicine for the treatment of immune disease is characterized in that this medicine is that Chinese medicine by following weight parts is prepared from:
Radix Arnebiae (Radix Lithospermi) 10~15
Radix Ginseng 3~5
Cornu Saigae Tataricae 2.5~6
Radix Panacis Quinquefolii 15~20
Radix Saposhnikoviae 30~40
Calculus Bovis 2~9
Unpeeled CORTEX MOUTAN 15~25
Cordyceps 8~15.
2, medicine according to claim 1 is characterized in that this medicine is that Chinese medicine by following weight parts is prepared from:
Radix Arnebiae (Radix Lithospermi) 12
Radix Ginseng 4
Cornu Saigae Tataricae 4
Radix Panacis Quinquefolii 18
Radix Saposhnikoviae 35
Calculus Bovis 5
Unpeeled CORTEX MOUTAN 20
Cordyceps 10.
3, medicine according to claim 1, the dosage form that it is characterized in that this medicine is a capsule.
4, medicine according to claim 1, the dosage form that it is characterized in that this medicine is a granule.
CN01104485A 2001-02-27 2001-02-27 Detoxicating and recovering medicine powder Expired - Lifetime CN1130215C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN01104485A CN1130215C (en) 2001-02-27 2001-02-27 Detoxicating and recovering medicine powder

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN01104485A CN1130215C (en) 2001-02-27 2001-02-27 Detoxicating and recovering medicine powder

Publications (2)

Publication Number Publication Date
CN1310007A CN1310007A (en) 2001-08-29
CN1130215C true CN1130215C (en) 2003-12-10

Family

ID=4653941

Family Applications (1)

Application Number Title Priority Date Filing Date
CN01104485A Expired - Lifetime CN1130215C (en) 2001-02-27 2001-02-27 Detoxicating and recovering medicine powder

Country Status (1)

Country Link
CN (1) CN1130215C (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4571952B2 (en) 2004-02-05 2010-10-27 アクセス ビジネス グループ インターナショナル リミテッド ライアビリティ カンパニー Antiallergic compositions and related methods

Also Published As

Publication number Publication date
CN1310007A (en) 2001-08-29

Similar Documents

Publication Publication Date Title
JP2015529670A (en) Chinese medicine composition for regulating immunity and method for producing the same
CN102145128A (en) Medicinal composition for preventing and treating cardiac and cerebral vascular diseases and preparation method thereof
CN1130215C (en) Detoxicating and recovering medicine powder
CN1225258C (en) Chinese medicine compound preparation for curing pancreatic cancer
CN1895593A (en) Medicine for treating acne and its preparation
CN101590092B (en) Traditional Chinese medicine combination for treating leukemia and preparation method thereof
CN101590103B (en) Traditional Chinese medicine combination for treating leukemia and preparation method thereof
CN105663684A (en) Medicine for treating aplastic anemia
CN1173718C (en) Medicine for curing lupus erythematosus etc. immune diseases induced diseases
CN1301544A (en) Medicinal composition for curing arthritis and osteoarthropathy and its preparing method
CN1333044A (en) Wasting-thirst hypoglycemic preparation
CN1537559A (en) Traditional Chinese medicine for treating AIDS
CN1126558C (en) Medicine for treating kidney damage caused by immunological disease lupus erythematosus
CN100553670C (en) A kind of pharmaceutical composition for the treatment of rheumatalgia
CN1036503C (en) Medicine for treating systemic lupus erythematosus and producing method thereof
CN1243560C (en) Medicine for treating dermatosis and its preparation method
CN1098705C (en) Oral medicine for treating cranial nerve system disease and preparation process thereof
CN105106855A (en) Traditional Chinese medicine preparation for treating apoplexy sequela
CN1167450C (en) Medicine for treating hyperosteogeny and bone retromorphosis and its preparing process
CN1245204C (en) Medicine for curing acute pharyngitis and its preparing method
CN1204916C (en) Medicine for treating depression and its preparation method
CN104840727B (en) Chinese medicine composition with anti-cancer of the esophagus activity and its preparation method and application
CN1198942A (en) Soothing and vexation relieving capsule and its preparation method
CN1468617A (en) Chinese medicine prepn for treating spondylosis
CN1136900C (en) Medicine for treating pulmonary tuberculosis and its preparing process

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20031210